S-1226

DRUG2 trials

Sponsors

SolAeroMed Inc.

Conditions

BronchiectasisCovid19Cystic FibrosisSARS-CoV-2 Infection

Phase 2

Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis

SolAeroMed Inc.Bronchiectasis, Cystic Fibrosis

Start: 2019-08-08End: 2022-08-31Target: 12Updated: 2021-06-16

Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia

SuspendedNCT04738136

SolAeroMed Inc.Covid19, SARS-CoV-2 Infection

Start: 2021-09-15End: 2021-12-31Target: 30Updated: 2021-08-23